Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.24 USD | +14.81% |
|
+46.57% | +57.96% |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 26.49 | 14.24 | 10.73 | 22.37 | - | - |
Enterprise Value (EV) 1 | 26.49 | 14.24 | 10.73 | 22.37 | 22.37 | 22.37 |
P/E ratio | -3.78 x | -1.14 x | -0.95 x | -1.51 x | -1.95 x | -2.88 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | 1.95 x |
EV / Revenue | - | - | - | - | - | 1.95 x |
EV / EBITDA | - | - | - | - | - | - |
EV / FCF | -17,024,599 x | - | - | - | - | - |
FCF Yield | -0% | - | - | - | - | - |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 10,768 | 11,674 | 13,666 | 18,037 | - | - |
Reference price 2 | 2.460 | 1.220 | 0.7850 | 1.240 | 1.240 | 1.240 |
Announcement Date | 4/14/22 | 3/22/23 | 4/5/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | 11.48 |
EBITDA | - | - | - | - | - | - | - |
EBIT 1 | - | -5.587 | -13.55 | -13.3 | -12.39 | -14.79 | -11.31 |
Operating Margin | - | - | - | - | - | - | -98.54% |
Earnings before Tax (EBT) 1 | - | -4.041 | -12.34 | -11.28 | -13.7 | -12.08 | -7.266 |
Net income 1 | -2.828 | -4.041 | -12.34 | -11.28 | -14.8 | -14.79 | -11.31 |
Net margin | - | - | - | - | - | - | -98.54% |
EPS 2 | -1.540 | -0.6500 | -1.070 | -0.8300 | -0.8200 | -0.6350 | -0.4300 |
Free Cash Flow | - | -1.556 | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 8/10/21 | 4/14/22 | 3/22/23 | 4/5/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -0.88 | -1.26 | -3.264 | -3.59 | -3.319 | -3.379 | -3.641 | -3.477 | -2.897 | -3.287 | -12.05 | -3.047 | -3.132 | -3.22 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -0.89 | -0.989 | -2.715 | -3.481 | -2.994 | -3.15 | -3.889 | - | 0.784 | -2.95 | -10.11 | -2.844 | -2.765 | -2.691 |
Net income 1 | -0.89 | -0.989 | -2.715 | -3.481 | -2.994 | -3.15 | -3.889 | -5.225 | 0.784 | -2.95 | -10.11 | -3.047 | -3.132 | -3.22 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.1500 | -0.0700 | -0.2400 | -0.3100 | -0.2500 | -0.2700 | -0.3300 | -0.4400 | 0.1000 | -0.1600 | -0.7400 | -0.1800 | -0.1750 | -0.1450 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 12/1/22 | 4/14/22 | 5/31/22 | 8/31/22 | 12/1/22 | 3/22/23 | 6/1/23 | 8/16/23 | 11/28/23 | 4/5/24 | 6/17/24 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow | - | -1.56 | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex | - | 0.02 | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 8/10/21 | 4/14/22 | 3/22/23 | 4/5/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+57.96% | 22.37M | |
+16.44% | 122B | |
+18.94% | 113B | |
+18.81% | 26.22B | |
-25.37% | 19.01B | |
-19.74% | 15.71B | |
-20.20% | 15.22B | |
-47.37% | 14.72B | |
+59.91% | 14.58B | |
+4.35% | 13.84B |
- Stock Market
- Equities
- NRSN Stock
- Financials NeuroSense Therapeutics Ltd.